Atlas Trials

Prognostic Value of "CD200" in Hematological Malignancies. Hematological Malignancies Comprise a Group of Malignant Clonal Disorders Arising From the Hematopoietic Tissues , Including Leukemia , Multiple Myeloma , and They Have a High Morbidity and Mortality

Clinical trial NCT06258629 · UNKNOWN

Trial details

NCT number
NCT06258629
Sponsor
Sohag University
Status
UNKNOWN
Study type
OBSERVATIONAL
Hematological Malignancies
Start date
2024-02-15
Primary completion
2025-02-06
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.